Latest News about RHHBY
Recent news which mentions RHHBY
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
From Benzinga
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
September 19, 2024
From Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
From Motley Fool
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
September 16, 2024
From Benzinga
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
September 13, 2024
From Motley Fool
Why Roche Holdings Stock Withered on Wednesday
September 11, 2024
From Motley Fool
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
September 09, 2024
From Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
From Benzinga
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
August 29, 2024
From Benzinga
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
August 26, 2024
From Benzinga
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
August 18, 2024
From Motley Fool
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
August 16, 2024
From Benzinga
From Benzinga
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
From Motley Fool
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
From Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
August 08, 2024
From Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
August 08, 2024
From Motley Fool
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
August 07, 2024
From Benzinga
From Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
From Motley Fool
From Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
From Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
From Motley Fool
From Benzinga
Tickers
RHHBY
From Motley Fool
From Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
From Benzinga
From Benzinga
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.